DexCom, Inc. (NASDAQ:DXCM) COO Sells $228,920.94 in Stock

DexCom, Inc. (NASDAQ:DXCM) COO Jacob Steven Leach sold 2,634 shares of the firm’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the sale, the chief operating officer now directly owns 268,644 shares of the company’s stock, valued at $23,347,850.04. The trade was a 0.97 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

DexCom Stock Performance

Shares of DexCom stock traded up $1.19 during trading hours on Thursday, hitting $87.62. 2,123,429 shares of the company were exchanged, compared to its average volume of 3,649,357. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. The business has a 50-day moving average of $80.22 and a 200-day moving average of $76.59. The stock has a market capitalization of $34.22 billion, a price-to-earnings ratio of 52.47, a P/E/G ratio of 2.23 and a beta of 1.12.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. JPMorgan Chase & Co. upped their price objective on DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a research report on Friday, October 25th. Wells Fargo & Company raised their target price on DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. Citigroup raised their price objective on DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Royal Bank of Canada cut their price target on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a research note on Friday, October 25th. Finally, StockNews.com downgraded DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Five analysts have rated the stock with a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $99.29.

Institutional Investors Weigh In On DexCom

Several large investors have recently modified their holdings of the stock. Creative Planning raised its position in DexCom by 4.9% in the second quarter. Creative Planning now owns 48,693 shares of the medical device company’s stock worth $5,521,000 after acquiring an additional 2,271 shares in the last quarter. NewEdge Advisors LLC raised its position in DexCom by 18.3% in the second quarter. NewEdge Advisors LLC now owns 9,020 shares of the medical device company’s stock worth $1,023,000 after acquiring an additional 1,393 shares in the last quarter. B. Riley Wealth Advisors Inc. raised its position in DexCom by 4.3% in the second quarter. B. Riley Wealth Advisors Inc. now owns 3,928 shares of the medical device company’s stock worth $445,000 after acquiring an additional 162 shares in the last quarter. New Wave Wealth Advisors LLC purchased a new position in DexCom in the second quarter worth $253,000. Finally, Brown Financial Advisors purchased a new position in DexCom in the second quarter worth $1,236,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.